Evolus to Participate in Two Upcoming Investor Conferences
IRVINE, Calif., June 14, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (“Evolus”) (NASDAQ:EOLS), a premiere aesthetics company, announced today that members of management will be participating in two upcoming investor conferences in New York, NY.
| Event: | Cantor 2018 Dermatology & Aesthetics Summit | ||||
| Panel: | Novel Aesthetic Dermatology Drugs and Devices for Unmet Needs | ||||
| Date: | Tuesday, June 19, 2018 | ||||
| Time: | 12:00 p.m. ET | ||||
| Location: | The Westin New York Grand Central, New York | ||||
| Event: | JMP Securities Life Sciences Conference | ||||
| Date: | Wednesday, June 20, 2018 | ||||
| Time: | 9:00 a.m. ET | ||||
| Location: | The St. Regis, New York | ||||
An audio webcast of the Company’s presentation at the JMP Securities Life Sciences Conference will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replays of the webcast will be available for 90 days after the date of the presentation.
About Evolus, Inc.
Evolus is a premiere aesthetics company focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead product candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that is being evaluated for the treatment of moderate to severe glabellar lines in adult patients.
Evolus Contacts:
Investor Contact:
Brian Johnston, The Ruth Group
Tel: +1 646-536-7028
Email: IR@Evolus.com
Media Contact:
Kirsten Thomas, The Ruth Group
Tel: +1-508-280-6592
Email: kthomas@theruthgroup.com